Studies show promise for fragile X treatment
Researchers have added two new candidates to the arsenal of compounds that alleviate both the behavioral and molecular hallmarks of fragile X syndrome in mice that model the disorder. A third candidate, minocycline, improves some symptoms in children with the disorder.